Cyclopharm (ASX:CYC) said its Technegas lung imaging product was recognized as a preferred ventilation agent in a new draft clinical guideline for lung imaging, according to a Tuesday filing with the Australian bourse.

The Procedure Standard and Guideline for Ventilation-Perfusion Pulmonary Scintigraphy recognized Technegas for clinical use in the US, designating it as a preferred ventilation agent when available, the filing said.

The draft guideline has been released for public consultation and will be refined for factual variations, per the filing.

Shares rose 13% in afternoon trade on Tuesday.